- Suven Life Sciences
Suven Life Sciences
NSE: SUVEN | BSE: 530239
₹130.95
+₹8.26 (6.73%) TodayLast updated on 05 May, 2025 | 15:55 ISTMarket cap  ₹2,676 Crs | Open ₹123.12 | Prev. Close ₹122.69 |
Circuit range ₹147.22 - ₹98.15 | Day range ₹123.00 - ₹131.79 | Year range ₹82.95 - ₹169.30 |
Volume 5,53,151 | Avg. traded ₹127.82 | Revenue (12m) ₹8 Crs |
About Suven Life Sciences
Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
Suven Life Sciences Share Price Chart
Please wait...
Suven Life Sciences Fundamentals
Suven Life Sciences Key indicators
52 week high ₹169.30 | 52 week low ₹82.95 | P/E ratio |
P/B ratio 18.97 | ROE -0.94% | ROCE -1.03% |
Dividend yield -- | Debt/Equity ratio | EPS -0.37 |
Featured in
Investment checklist: (2/6)
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst ratings:
100%
Hold
0%
Sell
0%
This analysis is based on the reviews of 1 experts in the last 7 days
Suven Life Sciences Financial Ratios
Operating profit margin-83.17% | Net profit margin-68.49% |
ROE-0.94% | ROA-0.89% |
ROCE-1.03% |
Quick ratio51.55 | Current ratio51.7 |
Interest coverage-36.47 | Asset turnover0.01 |
Debt to Equity0 |
P/E ratio0 | P/B ratio18.97 |
EV / EBITDA-207.8 | |
Dividend yield0% |
Revenue statement
All values are in ₹ Crores (Cr)
Loading chart data
Cash flow
All values are in ₹ Crores (Cr)
Loading chart data
Balance sheet
All values are in ₹ Crores (Cr)
No data available at the moment
Total assets
Total liabilities
Suven Life Sciences Share Price history
| Day | Open | Close | Change % |
|---|---|---|---|
Fri, May 2 2025 | ₹127.10 | ₹122.69 | -3.77% |
Wed, Apr 30 2025 | ₹130.87 | ₹127.50 | -2.63% |
Tue, Apr 29 2025 | ₹133.31 | ₹130.95 | -1.77% |
Mon, Apr 28 2025 | ₹134.50 | ₹133.31 | -1.97% |
Fri, Apr 25 2025 | ₹143.44 | ₹135.99 | -3.69% |
Thu, Apr 24 2025 | ₹130.50 | ₹141.20 | |
Wed, Apr 23 2025 | ₹130.00 | ₹130.10 | |
Tue, Apr 22 2025 | ₹127.63 | ₹129.42 |
More
Stocks Similar to Suven Life Sciences
Popular Stocks
Suven Life Sciences News
FAQs on Suven Life Sciences
What is the Suven Life Sciences share price today?
Suven Life Sciences share price is ₹ 130.95 as on 05 May, 2025 | 19:28 IST
What is today’s high & low share price of Suven Life Sciences?
Suven Life Sciences share price high: ₹ 131.79 and low: ₹ 123.00 as on 05 May, 2025 | 19:28 IST
What is the Suven Life Sciences share price high and low in the last 52 weeks on the NSE?
52 Week share High Price is ₹ 169.30 and Low Price is ₹ 82.95 as on 05 May, 2025 | 19:28 IST
What is the Suven Life Sciences Stock Symbol?
The Suven Life Sciences Stock symbol is SUVEN.
Can I buy Suven Life Sciences shares on Holidays?
No, shares of Suven Life Sciences or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Suven Life Sciences shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.